GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » Equity-to-Asset

Kyorin Pharmaceutical Co (TSE:4569) Equity-to-Asset : 0.71 (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Kyorin Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was 円126,575 Mil. Kyorin Pharmaceutical Co's Total Assets for the quarter that ended in Dec. 2023 was 円178,942 Mil. Therefore, Kyorin Pharmaceutical Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.71.

The historical rank and industry rank for Kyorin Pharmaceutical Co's Equity-to-Asset or its related term are showing as below:

TSE:4569' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.7   Med: 0.74   Max: 0.85
Current: 0.71

During the past 13 years, the highest Equity to Asset Ratio of Kyorin Pharmaceutical Co was 0.85. The lowest was 0.70. And the median was 0.74.

TSE:4569's Equity-to-Asset is ranked better than
69.4% of 1085 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs TSE:4569: 0.71

Kyorin Pharmaceutical Co Equity-to-Asset Historical Data

The historical data trend for Kyorin Pharmaceutical Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyorin Pharmaceutical Co Equity-to-Asset Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 0.72 0.75 0.72 0.71

Kyorin Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.73 0.71 0.72 0.72 0.71

Competitive Comparison of Kyorin Pharmaceutical Co's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyorin Pharmaceutical Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's Equity-to-Asset falls into.



Kyorin Pharmaceutical Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Kyorin Pharmaceutical Co's Equity to Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Equity to Asset (A: Mar. 2023 )=Total Stockholders Equity/Total Assets
=125460/176045
=0.71

Kyorin Pharmaceutical Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=126575/178942
=0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyorin Pharmaceutical Co  (TSE:4569) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Kyorin Pharmaceutical Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyorin Pharmaceutical Co (TSE:4569) Business Description

Traded in Other Exchanges
N/A
Address
6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co (TSE:4569) Headlines

No Headlines